Rentschler Biotechnologie expands European manufacturing capabilities with GE bioprocess technologies

GE Healthcare's automated and manufacturing scale chromatography system has gone into production

GE Healthcare celebrates with Rentschler Biotechnologie the installation of its 1,000th AKTAprocess automated process and manufacturing scale chromatography system

Rentschler Biotechnologie has held a joint celebration to mark the handover of GE Healthcare’s 1,000th ÄKTAprocess and the expansion of the German CDMO's biopharmaceutical manufacturing capabilities in Laupheim, Germany.

ÄKTAprocess, GE’s automated process and manufacturing scale chromatography system, has gone into operation as part of Rentschler’s recently expanded single-use manufacturing suite.

GE's biomanufacturing technologies such as the XDR 2000L bioreactor, the associated seed trains of 50, 200 and 500 L, as well as the new ÄKTAprocess, are expected to play a key role in Rentschler’s new production line.

Peter Rogge, VP USP Production, Rentschler, said: 'This line will further enhance our ability to deliver high quality projects for companies around the globe and is providing increased capacity in Europe of next-generation manufacturing capabilities. GE continues to have the innovative tools and expertise to deliver the high quality products and services demanded by companies like us.'

Emmanuel Ligner, GM Global Commercial, BioProcess, added: 'I am delighted to formally hand over the 1,000th ÄKTAprocess and to see the new single-use line featuring the GE XDR 2000L. Our relationship with Rentschler began almost 20 years ago and we are proud to have been able to support the company's growth over so many years.'

Companies